This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital malformations of cardiac septa심중격의 선천기형 (심중격선천기형)

Contents and key points
ItemDetails
A. Classification codesICD-10: Q21 (Congenital malformations of cardiac septa) | Special Copayment Reduction: V192 (Special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsVentricular septal defect (VSD), atrial septal defect (ASD), atrioventricular septal defect (AVSD), endocardial cushion defect
C. Adult onsetSmall VSDs/ASDs are asymptomatic and found incidentally in adulthood, while uncorrected moderate or larger defects progress to pulmonary hypertension and heart failure in adulthood.
1. HistoryRoger described VSD in 1879 (maladie de Roger); Gibbon succeeded in direct ASD closure under cardiopulmonary bypass in 1953
2. CausesFailure of endocardial cushion fusion (ASD, AVSD); abnormal muscular or perimembranous ventricular septal development (VSD)
3. GeneticsGATA4, NKX2-5, TBX5 (Holt-Oram); association of trisomy 21 (Down syndrome) with AVSD
4. General epidemiologyVSD 1/1,000 live births (most common congenital heart malformation), ASD 0.9/1,000; AVSD 0.2–0.35/1,000
5. PathophysiologyIncomplete endocardial cushion formation or failure of fusion between the muscular and membranous ventricular septal components
6. SymptomsSmall VSD: asymptomatic; large VSD/AVSD: feeding difficulty, poor weight gain, and rapid breathing in infancy; ASD: may be asymptomatic into adulthood
7. SignsVSD: holosystolic murmur at the left sternal border, 3rd–4th intercostal spaces; ASD: fixed split second heart sound; AVSD: holosystolic murmur plus combined murmurs
8. ScreeningNeonatal auscultation, pulse oximetry, prenatal fetal echocardiography, chest X-ray
9. DiagnosisTransthoracic/transesophageal echocardiography, cardiac MRI, cardiac catheterization (Qp/Qs, pulmonary vascular resistance), 3D echocardiography
10. TreatmentMild VSD/ASD: observation; moderate or greater: percutaneous device closure (ASD, muscular VSD) or surgical patch closure
11. PrognosisNear-normal life expectancy with early correction; uncorrected large defects carry a risk of Eisenmenger syndrome
12. PreventionFolic acid supplementation, enhanced prenatal diagnosis, genetic counseling (with family history or associated syndrome)
13. ReferencesGenetic Insights into Congenital Cardiac Septal Defects — A Narrative Review … and 9 other papers

1. History

Medical descriptions of septal defects date back to the 17th-century autopsy records of Nicolas Stensen, but their clinical importance was systematically recognized in the 19th century. In 1879, the French pediatrician Henri-Louis Roger clinically described asymptomatic children with ventricular septal defect (VSD) and reported that a characteristic harsh systolic murmur heard at the left sternal border is the hallmark finding of this malformation. In honor of this contribution, small muscular VSDs are still called 'maladie de Roger' today. For atrial septal defect (ASD), Rokitansky proposed a pathological classification in 1875, after which subtype classification into secundum, primum, sinus venosus, and coronary sinus defects was established.

In the first half of the 20th century, closed-chest surgery was the only means of correcting congenital heart malformations, and intracardiac surgery was impossible without cardiopulmonary bypass. This limitation was overcome in 1953 when John Gibbon directly closed an ASD using the heart-lung bypass machine he had developed, a monumental starting point for modern open-heart surgery. Complete surgical correction of VSD was first achieved in 1954 by Lillehei and colleagues using the cross-circulation technique. Surgical correction of atrioventricular septal defect (AVSD) advanced when Rastelli et al. established surgical techniques for endocardial cushion defects in 1966, and today the standard procedure of simultaneous bileaflet atrioventricular valve reconstruction and septal patch closure is established.

Interventional cardiology opened a new chapter in 1976 when King and Mills performed the first percutaneous ASD closure. After the Amplatzer Septal Occluder was introduced into clinical practice in 1997, percutaneous device closure of secundum ASDs and some VSDs became standard treatment. Today, percutaneous intervention is established as a major treatment replacing open-heart surgery in selected patients, and robot-assisted minimally invasive surgery has also been introduced, improving cosmetic results and recovery time.


2. Causes

The cause of septal defects is abnormality in the formation of the atrial or ventricular septum during embryonic development. Atrial septal development is a complex process in which two membranous structures—the septum primum and the septum secundum—form sequentially in the common atrial chamber and partially overlap. Depending on the abnormality in this process, secundum ASD (oval fossa defect), primum ASD (with endocardial cushion defect), sinus venosus ASD (defect at the junction of the superior or inferior vena cava), and coronary sinus ASD arise.

The ventricular septum consists of muscular and membranous components, and the growth and fusion of each component must combine to form a complete septum. Perimembranous VSD accounts for about 80% of all VSDs and is caused by failure of fusion among the endocardial cushion tissue, the muscular septum, and the membranous septal components. Muscular VSD results from tissue loss or incomplete growth within the muscular septum and may be multiple ('swiss cheese' VSD). Atrioventricular septal defect (AVSD) is a malformation in which, due to incomplete fusion of the endocardial cushions, primum ASD, ventricular septal defect (inlet type), and atrioventricular valve abnormality (common atrioventricular valve) occur in combination.

Most cases have multifactorial causes, with contributions from genetic predisposition and environmental factors. Known environmental risk factors include rubella infection in early pregnancy, alcohol, phenytoin, and valproic acid. Maternal diabetes increases the risk of septal defects, including AVSD, 2–3-fold. Down syndrome (trisomy 21) is particularly strongly associated with AVSD; congenital heart malformations accompany about 45–50% of children with Down syndrome, and AVSD is the most common of these.


3. Genetics

The genetics of septal defects are not simple, ranging from single-gene mutations to chromosomal abnormalities and multifactorial inheritance. NKX2-5 transcription factor variants are an autosomal dominant trait causing both atrial septal defect (especially secundum type) and atrioventricular conduction abnormalities (atrioventricular block), and are an important cause of familial ASD. GATA4 variants are associated with secundum ASD and VSD, and in particular GATA4 haploinsufficiency due to 8p23.1 deletion causes septal defects.

TBX5 variants are the causative gene of Holt-Oram syndrome, presenting with a phenotype of atrial or ventricular septal defect accompanied by upper limb malformations (radial defects, abnormal thumb development, etc.). Holt-Oram syndrome must be differentiated in patients with septal defects. Trisomy 21 (Down syndrome) has the strongest association with AVSD, and the DSCAM, COL6A1/A2, and DSCR1 genes on chromosome 21 are presumed to be involved in the development of AVSD.

Chromosome 22q11.2 deletion (DiGeorge syndrome) is accompanied by some VSDs in addition to conotruncal malformations, and standard FISH or chromosomal microarray screening is recommended in patients with septal defects. Genome-wide association studies (GWAS) showed significant associations of polymorphisms near MSX1, CRELD1, and other developmental genes with VSD and AVSD. Because de novo mutations can cause complex septal defects even in genetically negative patients, whole-exome analysis is considered in severe malformations without a family history.


4. General epidemiology

Septal defects, including atrial and ventricular septal defects, form the most common category of congenital heart malformations. Ventricular septal defect (VSD) is the most common single malformation among congenital heart diseases, with a reported incidence of about 0.99–3.5 per 1,000 live births, varying with the diagnostic criteria of studies and whether small muscular VSDs are included. Atrial septal defect (ASD) is the second most common malformation after VSD at about 0.9–1.3 per 1,000 live births, and is about twice as frequent in females.

Atrioventricular septal defect (AVSD) is relatively rare at about 0.2–0.35 per 1,000 live births, but its prevalence is much higher in children with Down syndrome, with complete AVSD present in about 35–40% of patients with Down syndrome. In Korea, according to analyses of health insurance data, a substantial portion of diagnoses of congenital heart malformations in infancy fall in the Q21 group, and among surgical cases, moderate or larger defects requiring open-heart surgery continue to be reported. Small secundum ASDs found incidentally in adulthood are being diagnosed more frequently as use of echocardiography expands.

Tetralogy of Fallot (TOF; Q21.3) is the representative complex malformation of the Q21 group, occurring in about 0.3–0.4 per 1,000 live births, and is the most common cyanotic congenital heart disease. TOF is a malformation combining four structural abnormalities: pulmonary stenosis, ventricular septal defect (VSD), overriding aorta, and right ventricular hypertrophy. Overall, in the septal defect group, complication rates and mortality have decreased greatly compared with the past owing to early diagnosis and advances in surgical techniques.


5. Pathophysiology

The pathophysiology of septal defects is based on the molecular mechanisms and morphogenetic abnormalities of embryonic heart development. In ASD, temporal or spatial abnormality between formation of the septum primum and septum secundum is key. If the ostium primum closes prematurely before the septum primum has grown sufficiently, or the ostium secundum forms excessively, secundum ASD develops. If the septum secundum does not grow sufficiently or fails to fuse with the endocardial cushion tissue, primum ASD and AVSD result.

The pathophysiology of VSD is failure of mutual growth and fusion of the multiple components of the ventricular septum (muscular septum, conal septum, membranous component derived from the endocardial cushions). The BMP (bone morphogenetic protein) and Notch signaling pathways are central to endocardial cushion formation and completion of the ventricular septum, and abnormalities in these pathways form the molecular basis of perimembranous VSD and atrioventricular inlet VSD. Because neural crest cells contribute to completion of the conal septum, abnormal neural crest cell migration causes conal VSD (including subarterial VSD and the VSD of tetralogy of Fallot).

Tetralogy of Fallot (TOF) is a malformation combining anterior deviation of the conal septum and pulmonary stenosis, and VEGF signaling deficiency or TBX1 haploinsufficiency due to 22q11.2 deletion is understood to cause abnormal conal development. In AVSD, abnormalities in TGF-β, EGF, and ErbB receptor signaling involved in the proliferation, migration, and differentiation of endocardial cushion cells cause the combined defect of the common atrioventricular valve and the atrial and ventricular septa.


6. Symptoms

Symptoms of septal defects vary greatly with the size and type of the defect, the shunt direction, and associated malformations. Small VSDs are detected by auscultation from the neonatal period but mostly close spontaneously and cause no clinical symptoms. In moderate or larger VSDs, as pulmonary vascular resistance falls at 4–8 weeks after birth, the left-to-right shunt increases and symptoms of congestive heart failure appear, such as feeding difficulty, sweating, poor weight gain, tachypnea, and recurrent respiratory infections.

ASD is asymptomatic through childhood in most cases, and reduced exercise capacity, fatigue, palpitations (atrial fibrillation/flutter), and dyspnea sometimes first appear in adulthood. Uncorrected large ASDs can progress over decades to pulmonary hypertension and then to Eisenmenger syndrome (reversal to a right-to-left shunt causing cyanosis). In AVSD, severe congestive heart failure symptoms (feeding refusal, severe tachypnea) appear early in infancy, and pulmonary hypertension tends to progress rapidly when Down syndrome is present. Tetralogy of Fallot is characterized by cyanosis, hypercyanotic spells (tet spells, acute hypoxic spells due to spasmodic contraction of the right ventricular outflow tract), and postural squatting.


7. Signs

The typical auscultatory finding of VSD is a harsh, high-pitched holosystolic murmur heard at the lower left sternal border (3rd–4th intercostal spaces). The larger the defect, the greater the shunt volume, causing secondary left ventricular hypertrophy and pulmonary hypertension, and the pulmonary component of the second heart sound (P2) is accentuated. When it progresses to Eisenmenger syndrome, the murmur actually decreases or disappears, and cyanosis and accentuated P2 become prominent.

The characteristic auscultatory finding of ASD is fixed splitting of S2, in which P2 is heard delayed relative to A2 regardless of the respiratory cycle. This is because right ventricular ejection time is prolonged by right ventricular volume overload from the ASD left-to-right shunt. In AVSD, the VSD murmur and the fixed split second heart sound of ASD combine, and a regurgitant murmur of the common atrioventricular valve is added. In tetralogy of Fallot, a systolic ejection murmur due to pulmonary stenosis is heard at the upper left sternal border, and cyanosis and clubbing of the fingers and toes are observed. During a hypercyanotic spell, the pulmonary stenosis murmur disappears and findings of severe hypoxemia appear.


8. Screening

Screening for septal defects takes place at several levels from the prenatal stage to the neonatal period. Prenatally, large VSDs, AVSD, tetralogy of Fallot, and others can be screened by cardiac structural evaluation including the four-chamber view and great artery views on the detailed ultrasound at 18–22 weeks of gestation. Prenatal detection rates vary by malformation type: about 60–80% for AVSD and TOF each, and less than 30% for small VSDs.

After birth, neonatal auscultation and pulse oximetry are the basis of screening. Pulse oximetry is useful for screening cyanotic congenital heart malformations (including TOF), but VSDs and ASDs that do not cause cyanosis are difficult to detect early. In such cases, clinical symptoms such as feeding difficulty, poor weight gain, and tachypnea, along with physical auscultation, provide important clues. Chest X-ray shows cardiomegaly (left or right ventricular enlargement), increased pulmonary vascularity (pulmonary overcirculation), or decreased pulmonary vascularity (boot-shaped heart in TOF).


9. Diagnosis

Transthoracic echocardiography (TTE) is the primary diagnostic tool for septal defects, noninvasively evaluating the location, size, and direction of the defect, shunt volume (Qp/Qs), ventricular function, and pulmonary artery pressure. With Doppler ultrasound, the right–left pressure gradient can be calculated from the shunt velocity and the presence of pulmonary hypertension estimated. Transesophageal echocardiography (TEE) is essential for evaluating the defect rims before percutaneous device closure, precise measurement of secundum ASD, and intraoperative monitoring.

Cardiac MRI (CMR) is used for accurate measurement of Qp/Qs, evaluation of right ventricular volume and function, and assessment of myocardial fibrosis. In particular, CMR is the standard test for quantitative evaluation of pulmonary regurgitant volume and right ventricular function after TOF surgery. Cardiac catheterization evaluates progression to Eisenmenger syndrome through pulmonary vascular resistance measurement and oxygen reactivity testing, and is used to determine indications for percutaneous procedures. Genetic testing is performed to differentiate syndromic congenital heart malformations such as Down syndrome (AVSD), Holt-Oram syndrome, and DiGeorge syndrome.


10. Treatment

The treatment approach is determined by the size and type of the defect, its hemodynamic impact, and the patient's age. About 30–50% of small muscular VSDs close spontaneously, so observation is appropriate if there are no signs of heart failure or pulmonary hypertension. For clinically significant VSDs (Qp/Qs ≥2.0 or left ventricular hypertrophy, feeding difficulty), medical heart failure treatment such as diuretics and caloric supplementation is given first, and surgical correction by patch repair is performed preferably at 3–6 months of age and no later than 1 year of age.

For secundum ASD, correction is indicated when the defect diameter is 5 mm or greater and there is evidence of right ventricular volume overload. If the defect rims are sufficient (≥5 mm), transcatheter device closure, such as with the Amplatzer Septal Occluder, is recommended as first-line, with fewer complications and faster recovery than surgery. Primum ASD and AVSD cannot be treated percutaneously and require surgical patch closure and atrioventricular valve reconstruction. Tetralogy of Fallot is generally treated with total intracardiac repair at 3–12 months of age, which includes VSD patch closure and enlargement of the right ventricular outflow tract.


11. Prognosis

After early diagnosis and appropriate correction, the long-term prognosis of patients with septal defects is generally favorable. Small VSDs close spontaneously or follow an asymptomatic course, allowing a normal life. Surgical mortality after surgical correction of moderate or larger VSDs is less than 0.5–2%, and 10-year survival exceeds 95%. The technical success rate after percutaneous closure of secundum ASD exceeds 95%, and arrhythmia (atrial fibrillation) may occur as a residual complication, so follow-up into adulthood is needed.

The 30-day mortality of AVSD repair is 2–5%, and the main long-term complications are recurrent atrioventricular valve regurgitation (about 5–15%), atrioventricular block, and left ventricular outflow tract obstruction. The 30-year survival after total repair of tetralogy of Fallot reaches 85–90%, but right ventricular failure due to cumulative pulmonary regurgitation and ventricular tachycardia are the main causes of long-term complications. When uncorrected large VSDs/ASDs progress to Eisenmenger syndrome, only medical treatment (pulmonary arterial hypertension–targeted therapy) is possible, and combined heart-lung transplantation becomes the only surgical option, with a poor prognosis.


12. Prevention

Absolute prevention of septal defects is currently impossible, but poor outcomes can be prevented through risk factor reduction and prenatal screening. Folic acid supplementation (0.4–5 mg/day) before and in early pregnancy significantly reduces the risk of congenital heart malformations. In mothers with maternal diabetes, strict blood glucose control from before conception is an effective preventive strategy for reducing the risk of heart malformations. Checking rubella vaccination status in early pregnancy and preventing viral infections during pregnancy are important.

In families with a history of Down syndrome or in mothers of advanced age, early detection of AVSD is possible through prenatal chromosomal testing (amniocentesis, chorionic villus sampling) and detailed fetal echocardiography. When there is a family history of congenital heart disease, the recurrence risk increases (recurrence rate in offspring of 3–5% when a parent has ASD), so detailed fetal echocardiography at a specialized cardiac center is strongly recommended during pregnancy. Families carrying Holt-Oram syndrome (TBX5 variant) or NKX2-5 variants should receive genetic counseling to assess disease risk and recurrence rate. Adult patients with congenital heart disease should undergo a comprehensive assessment of maternal cardiovascular risk and fetal heart malformation risk through consultation with a specialist before pregnancy.


13. References

  1. Kalman JM, Bhatt DL, Bhave PD, et al. Genetic Insights into Congenital Cardiac Septal Defects: A Narrative Review. Biology. 2024;13(11):911. DOI: 10.3390/biology13110911. PMID: 39596866.

  2. Botto LD, Correa A, Erickson JD. Racial and temporal variations in the prevalence of heart defects. Pediatrics. 2001;107(3):E32. DOI: 10.1542/peds.107.3.e32. PMID: 11230618.

  3. Du ZD, Hijazi ZM, Kleinman CS, et al. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. Journal of the American College of Cardiology. 2002;39(11):1836–1844. DOI: 10.1016/s0735-1097(02)01862-4. PMID: 12039492.

  4. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease. Journal of the American College of Cardiology. 2019;73(12):e81–e192. DOI: 10.1016/j.jacc.2018.08.1029. PMID: 30121239.

  5. Jacobs JP, Burke RP, Quintessenza JA, et al. Congenital Heart Surgery Nomenclature and Database Project: ventricular septal defect. Annals of Thoracic Surgery. 2000;69(4 Suppl):S25–S35. DOI: 10.1016/s0003-4975(99)01270-9. PMID: 10798418.

  6. Lindinger A, Schwedler G, Hense HW. Prevalence of congenital heart defects in newborns in Germany: Results of the first registration year of the PAN Study. Klinische Pädiatrie. 2010;222(5):321–326. DOI: 10.1055/s-0030-1254155. PMID: 20799151.

  7. Lange R, Herer B, Müller C, et al. Outcomes after atrioventricular septal defect repair. European Journal of Cardio-Thoracic Surgery. 2014;45(3):501–509. DOI: 10.1093/ejcts/ezt438. PMID: 24014661.

  8. Pierpont ME, Brueckner M, Chung WK, et al. Genetic basis for congenital heart disease: Revisited: A scientific statement from the American Heart Association. Circulation. 2018;138(21):e653–e711. DOI: 10.1161/CIR.0000000000000606. PMID: 30571578.

  9. Hoffman JI, Kaplan S. The incidence of congenital heart disease. Journal of the American College of Cardiology. 2002;39(12):1890–1900. DOI: 10.1016/s0735-1097(02)01886-7. PMID: 12084585.

  10. Zhao QM, Liu F, Wu L, et al. Prevalence of congenital heart disease at live birth in China. Journal of Pediatrics. 2019;204:53–58. DOI: 10.1016/j.jpeds.2018.08.040. PMID: 30274736.